🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "major milestone" in the fight against superbug strains of the infection, according to researchers.

A Global Public Health Issue

Cases of gonorrhoea are on the rise around the world, with data suggesting in excess of 82 million infections each year. Particularly high rates are seen in Africa and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune step in the reality of increasing worldwide cases, the spread of superbugs and the highly restricted available drugs presently on offer.”

Public health authorities are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "high-priority threat". A tracking program revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Therapies Gain Approval

One new antibiotic, alternatively called Nuzolvence, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers believe that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, was also approved in close succession. This treatment, which is additionally indicated for UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This milestone signifies a huge turning point in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Research Study Data and Global Access

As per findings published in a prominent scientific publication, zoliflodacin cured more than 90% of uncomplicated infections. This establishes an equal footing with the current standard treatment, which combines two antibiotics. The research involved nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the ability to make available and distribute the drug in many regions with limited resources.

Doctors on the front lines have shared optimism. Access to a single-dose, oral treatment such as this is seen as a "critical tool" for gonorrhoea control. This is viewed as vital to reduce the burden of the infection for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.